Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Average Price Target from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $16.00.

Several research analysts have issued reports on COYA shares. Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, March 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday. Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Friday, April 10th.

Institutional Investors Weigh In On Coya Therapeutics

A number of large investors have recently bought and sold shares of COYA. Jane Street Group LLC increased its holdings in Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Coya Therapeutics in the second quarter valued at $119,000. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics in the third quarter valued at $28,000. CM Management LLC raised its holdings in shares of Coya Therapeutics by 50.0% in the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after buying an additional 100,000 shares during the last quarter. Finally, Dauntless Investment Group LLC lifted its position in Coya Therapeutics by 199.5% during the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after buying an additional 101,932 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Trading Down 2.6%

NASDAQ COYA opened at $4.41 on Friday. The stock’s 50 day moving average is $4.51 and its two-hundred day moving average is $5.26. The company has a market capitalization of $103.46 million, a price-to-earnings ratio of -3.47 and a beta of 0.51. Coya Therapeutics has a 1-year low of $3.71 and a 1-year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The company had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%. On average, analysts predict that Coya Therapeutics will post -1.81 earnings per share for the current year.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.